

# Author's Accepted Manuscript

The PI3K Pathway: Clinical Inhibition in CLL

Jennifer R. Brown MD PhD



PII: S0093-7754(16)00010-5  
DOI: <http://dx.doi.org/10.1053/j.seminoncol.2016.02.004>  
Reference: YSONC51908

[www.elsevier.de/ending](http://www.elsevier.de/ending)

To appear in: *Semin Oncol*

Cite this article as: Jennifer R. Brown MD PhD, The PI3K Pathway: Clinical Inhibition in CLL, *Semin Oncol*, <http://dx.doi.org/10.1053/j.seminoncol.2016.02.004>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**The PI3K Pathway: Clinical Inhibition in CLL****Jennifer R Brown MD PhD****Director, CLL Center, Department of Medical Oncology, Dana-Farber Cancer Institute,  
Boston, MA; Department of Medicine, Harvard Medical School, Boston, MA****Correspondence should be addressed to Jennifer R Brown, MD, PhD, Dana-Farber Cancer  
Institute, 450 Brookline Avenue, Boston, MA 02215; telephone 617-632-4564; fax 617-582-  
7890; email [jbrown2@partners.org](mailto:jbrown2@partners.org)****Abstract**

Constitutive or mutational activation of the phosphatidylinositol 3 kinase, or PI3K, has been implicated in many cancers, including CLL. The delta isoform of the p110 catalytic subunit of PI3K has its primary physiologic function in B cells and appears to be the predominant mediator of most PI3K signals in CLL cells. Idelalisib is a first-in-class inhibitor of the PI3K delta isoform which shows near complete inhibition of AKT phosphorylation in CLL cells in vitro and in vivo. Idelalisib shows the classic pattern of response to BCR inhibition in CLL, with rapid nodal response and transient increase in lymphocytosis. The phase 1 study established the recommended dose as 150 mg twice per day. Subsequent registration trials have

Download English Version:

<https://daneshyari.com/en/article/2161750>

Download Persian Version:

<https://daneshyari.com/article/2161750>

[Daneshyari.com](https://daneshyari.com)